Julen
Oyarzabal Santamarina
Investigador hasta 2018
Publicaciones (108) Publicaciones de Julen Oyarzabal Santamarina
2024
-
AI is a viable alternative to high throughput screening: a 318-target study
Scientific Reports, Vol. 14, Núm. 1
-
Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)
Scientific Reports
-
Epigenetic-based differentiation therapy for Acute Myeloid Leukemia
Nature Communications, Vol. 15, Núm. 1
2022
-
CM-352 Efficacy in a Mouse Model of Anticoagulant-Associated Intracranial Hemorrhage
Thrombosis and Haemostasis, Vol. 122, Núm. 8, pp. 1314-1325
2021
-
Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with in Vivo Efficacy in Multiple Myeloma
Journal of Medicinal Chemistry, Vol. 64, Núm. 6, pp. 3392-3426
-
Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma
Hepatology, Vol. 73, Núm. 6, pp. 2380-2396
-
Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death
Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285
-
Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: Dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis
Gut, Vol. 70, Núm. 2, pp. 388-400
-
Searching for peptide inhibitors of t regulatory cell activity by targeting specific domains of foxp3 transcription factor
Biomedicines, Vol. 9, Núm. 2, pp. 1-20
-
Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease
Nature Communications, Vol. 12, Núm. 1
-
mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks
Molecular Therapy - Nucleic Acids, Vol. 25, pp. 207-219
2020
-
2-Oxaadamant-1-yl Ureas as Soluble Epoxide Hydrolase Inhibitors: In Vivo Evaluation in a Murine Model of Acute Pancreatitis
Journal of medicinal chemistry, Vol. 63, Núm. 17, pp. 9237-9257
-
A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity
Cancer Letters, Vol. 468, pp. 1-13
-
Dual pharmacological targeting of hdacs and pde5 inhibits liver disease progression in a mouse model of biliary inflammation and fibrosis
Cancers, Vol. 12, Núm. 12, pp. 1-27
-
Re: Inhibition of a G9a/DNMT Network Triggers Immune-Mediated Bladder Cancer Regression
Journal of Urology
-
Towards the understanding of the activity of G9a inhibitors: an activity landscape and molecular modeling approach
Journal of Computer-Aided Molecular Design, Vol. 34, Núm. 6, pp. 659-669
2019
-
Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class i Histone Deacetylase Selective Inhibitors
ACS Chemical Neuroscience, Vol. 10, Núm. 3, pp. 1765-1782
-
Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors
European Journal of Medicinal Chemistry, Vol. 168, pp. 87-109
-
Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma
Hepatology, Vol. 69, Núm. 2, pp. 587-603
-
Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
Nature Medicine